The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains

Antiviral Therapy

Volumn 12, Issue 6, 2007, Pages 865-876

  Ren, Guang Li ^a   Fang, Ying ^b   Ma, Heng Hao ^a   Lei, Ying Feng ^c   Wang, Dan ^a   Xu, Man Chun ^a   Wang, Ping Zhong ^c   Huang, Chang Xing ^c   Nie, Qing He ^c   Sun, Yong Tao ^c   Bai, Xue Fan ^c  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b Department of Pathology   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA POLYMERASE; SHORT HAIRPIN RNA; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION; DRUG EFFICACY; DRUG MECHANISM; GENE SILENCING; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; VIRUS EXPRESSION; VIRUS GENE; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RNA INTERFERENCE; RNA POLYMERASE II; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 34848852743     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346:1682-1683.
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31:339-346.
3. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403.
4. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43:1385-1391.
5. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-1425.
6. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
7. Denman RB. Hairpin ribozyme specificity in vivo: a case of promiscuous cleavage. Biochem Biophys Res Commun 1999; 257:356-360.
8. Boehm M, Slack F. A developmental timing microRNA and its target regulate life span in C. elegans. Science 2005; 310:1954-1957.
9. Mello CC, Conte D Jr. Revealing the world of RNA interference. Nature 2004; 431:338-342.
10. Hannon GJ. RNA interference. Nature 2002; 418:244-251.
11. Zamore PD, Tuschl T, Sharp PA, et al. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101:25-33.
12. Plasterk RH. RNA silencing: the genome's immune system. Science 2002; 296:1263-1265.
13. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2:243-247.
14. Martinez MA, Gutierrez A, Armand-Ugon M, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002; 16:2385-2390.
15. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005; 23:1002-1007.
16. Korf M, Jarczak D, Beger C, et al. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol 2005; 43:225-234.
17. Guo Y, Guo H, Zhang L, et al. Genomic analysis of anti-hepatitis B virus (HBV) activity by small interfering RNA and lamivudine in stable HBV-producing cells. J Virol 2005; 79:14392-14403.
18. Wu HL, Huang LR, Huang CC, et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005; 128:708-716.
19. Uprichard SL, Boyd B, Althage A, et al. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci U S A 2005; 102:773-778.
20. Klein C, Bock CT, Wedemeyer H, et al. Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003; 125:9-18.
21. Carmona S, Ely A, Crowther C, et al. Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther 2006; 13:411-421.
22. Ren GL, Bai XF, Zhang Y, et al. Stable inhibition of hepatitis B virus expression and replication by expressed siRNA. Biochem Biophys Res Commun 2005; 335:1051-1059.
23. Gunther S, Li BC, Miska S, et al. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-5444.
24. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res 2005; 33:1834-1847.
25. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21:635-637.
26. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12:1179-1187.
27. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441:537-541.
28. Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004; 22:326-330.
29. Santoyo J, Vaquerizas JM, Dopazo J. Highly specific and accurate selection of siRNAs for high-throughput functional assays. Bioinformatics 2005; 21:1376-1382.
30. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005; 30:106-114.
31. Hamilton A, Voinnet O, Chappell L, et al. Two classes of short interfering RNA in RNA silencing. Embo J 2002; 21:4671-4679.
32. Zhou H, Xia XG, Xu Z. An RNA polymerase II construct synthesizes short-hairpin RNA with a quantitative indicator and mediates highly efficient RNAi. Nucleic Acids Res 2005; 33:e62.
33. Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J 2004; 23:4051-4060.
34. Chung KH, Hart CC, Al-Bassam S, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006; 34:e53.
35. Lecocq M, Andrianaivo F, Warnier MT, et al. Uptake by mouse liver and intracellular fate of plasmid DNA after a rapid tail vein injection of a small or a large volume. J Gene Med 2003; 5:142-156.
36. Tzung SP, Fausto N, Hockenbery DM. Expression of Bcl-2 family during liver regeneration and identification of Bcl-x as a delayed early response gene. Am J Pathol 1997; 150:1985-1995.
37. Schlossberg H, Zhang Y, Dudus L, et al. Expression of c-fos and c-jun during hepatocellular remodeling following ischemia/reperfusion in mouse liver. Hepatology 1996; 23:1546-1555.
38. Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78:2601-2605.
39. Westerhout EM, Ooms M, Vink M, et al. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res 2005; 33:796-804.
40. Matzke MA, Birchler JA. RNAi-mediated pathways in the nucleus. Nat Rev Genet 2005; 6:24-35.